keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM).
説明 | TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM). |
ターゲット&IC50 | EGFR:1.1-8.0 nM |
In vitro | TAS6417 inhibits the growth of cells expressing exon 20 insertion mutations of the EGFR gene (GI50 value of 86.5±28.5 nM for LXF 2478L cells and 45.4±2.6 nM for NCI-H1975 EGFR D770_N771insSVD cells). TAS6417 also potently inhibits proliferation in other cell lines harboring activating mutations or acquired resistance mutations (mean GI50: 1.92±0.21 nM to 7.12±0.60 nM) [1]. |
In vivo | TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues. TAS6417 induces persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models [1]. |
分子量 | 396.44 |
分子式 | C23H20N6O |
CAS No. | 1661854-97-2 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (138.73 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TAS6417 1661854-97-2 Angiogenesis Apoptosis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR ErbB-1 TAS-6417 PC-9 lung Inhibitor CLN081 BEAS-2B CLN 081 cancer BID007 CLN-081 inhibit NSCLC H1975 Epidermal growth factor receptor BID019 HER1 Akt TAS 6417 inhibitor